{"id":"NCT00792909","sponsor":"GlaxoSmithKline","briefTitle":"Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A","officialTitle":"Vaccination Course in Children Primed and Boosted With Pneumococcal Vaccine GSK 1024850A and in Age-matched Unprimed Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-02","primaryCompletion":"2009-07-02","completion":"2009-07-02","firstPosted":"2008-11-18","resultsPosted":"2017-12-14","lastUpdate":"2017-12-14"},"enrollment":172,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]}],"arms":[{"label":"Synflorix™ Group 1","type":"EXPERIMENTAL"},{"label":"Synflorix™ Group 2","type":"EXPERIMENTAL"},{"label":"Unprimed Group","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to assess the immune memory induced by primary and booster vaccination with pneumococcal conjugate vaccine GSK1024850A in the first year of life through evaluation of the immune responses following vaccination with a booster dose of pneumococcal conjugate vaccine GSK1024850A in the fourth year of life and to assess immune responses following vaccination with a single dose of pneumococcal conjugate vaccine GSK1024850A in age-matched unprimed children.\n\nThe study also aims to assess the antibody persistence in the fourth year of life following primary and booster vaccination with pneumococcal conjugate vaccine GSK1024850A in the first year of life.\n\nThe study is also designed to evaluate the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following a 2-dose vaccination with pneumococcal conjugate vaccine GSK1024850A in the fourth year of life.\n\nThis protocol posting deals with objectives \\& outcome measures of the booster phase. The objectives \\& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = 00307034)","primaryOutcome":{"measure":"Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group","timeFrame":"Pre-vaccination (PRE/ Day 0)","effectByArm":[{"arm":"Unprimed Group","deltaMin":0.06,"sd":null}],"pValues":[]},"eligibility":{"minAge":"36 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":5,"countries":["Slovakia","Sweden"]},"refs":{"pmids":["21572373"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":51},"commonTop":["Pain","Redness","Swelling","Irritability","Drowsiness"]}}